WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562055

CAS#: 5322-53-2

Description: Oxiperomide is a dopamine D2 and muscarinic M1 receptor ligand with putative antipsychotic and pro-cognitive potential.

Chemical Structure

CAS# 5322-53-2

Theoretical Analysis

MedKoo Cat#: 562055
Name: Oxiperomide
CAS#: 5322-53-2
Chemical Formula: C20H23N3O2
Exact Mass: 337.179
Molecular Weight: 337.42
Elemental Analysis: C, 71.19; H, 6.87; N, 12.45; O, 9.48

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Oxiperomide; Peromide;

IUPAC/Chemical Name: 3-[1-(2-Phenoxyethyl)piperidin-4-yl]-1H-benzimidazol-2-one


InChi Code: InChI=1S/C20H23N3O2/c24-20-21-18-8-4-5-9-19(18)23(20)16-10-12-22(13-11-16)14-15-25-17-6-2-1-3-7-17/h1-9,16H,10-15H2,(H,21,24)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 337.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Gerhardt S, Gerber R, Liebman JM. SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models. Life Sci. 1985 Dec 23;37(25):2355-63. PubMed PMID: 3908866.

2: Costall B, Kelly ME, Naylor RJ. Unilateral striatal dopamine denervation: reduced motor inhibitory effects of dopamine antagonists revealed in models of asymmetric and circling behaviour. Naunyn Schmiedebergs Arch Pharmacol. 1984 May;326(1):29-35. PubMed PMID: 6433208.

3: Bischoff S, Bittiger H, Delini-Stula A, Ortmann R. Septo-hippocampal system: target for substituted benzamides. Eur J Pharmacol. 1982 Apr 23;79(3-4):225-32. PubMed PMID: 7201401.

4: Costall B, Lim SK, Naylor RJ. Characterisation of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity of mice. Eur J Pharmacol. 1981 Jul 17;73(2-3):175-88. PubMed PMID: 6118281.

5: Neale R, Fallon S, Gerhardt S, Liebman JM. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7. PubMed PMID: 6798615.

6: Liebman JM, Neale R, Noreika L, Braunwalder A. Differential reversal of various dopamine antagonists by anticholinergics in Sidman avoidance: possible relationship to adrenergic blockade. Psychopharmacology (Berl). 1981;75(3):248-53. PubMed PMID: 6119730.

7: Porsolt RD, Jalfre M. Neuroleptic-induced acute dyskinesias in rhesus monkeys. Psychopharmacology (Berl). 1981;75(1):16-21. PubMed PMID: 6117919.

8: Owen RT. Intrastriatal kainic acid- a possible model for antidyskinetic/antichoreic agents? Methods Find Exp Clin Pharmacol. 1980 Apr;2(3):133-7. PubMed PMID: 7339335.

9: Casey DE, Gerlach J. Oxiperomide in tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1980 Mar;43(3):264-7. PubMed PMID: 7373324; PubMed Central PMCID: PMC490519.

10: Hyttel J. Further evidence that 3H-cis(Z)flupenthixol binds to the adenylate cyclase-associated dopamine receptor (D-1) in rat corpus striatum. Psychopharmacology (Berl). 1980 Jan;67(1):107-9. PubMed PMID: 6768074.

11: Bjørndal N, Casey D, Gerlach J. Dopamine antagonist and agonist treatment of tardive dyskinesia. Adv Biochem Psychopharmacol. 1980;24:541-5. PubMed PMID: 6105800.

12: Costall B, Naylor RJ, Nohria V. Use of the mouse circling model to demonstrate enhanced striatal actions for oxiperomide and tiapride following denervation [proceedings]. Br J Pharmacol. 1979 May;66(1):121P. PubMed PMID: 36952; PubMed Central PMCID: PMC2043833.

13: Casey DE, Gerlach J. Sulpiride and oxiperomide in tardive dyskinesia. Trans Am Neurol Assoc. 1979;104:210-1. PubMed PMID: 553412.

14: Costall B, Naylor RJ. Dopamine antagonistic effects of a series of analogues of oxiperomide and spiroxatrine measured behaviourally in the rodent. J Pharm Pharmacol. 1978 Nov;30(11):693-8. PubMed PMID: 31432.

15: Costall B, Naylor RJ, Nohria V. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur J Pharmacol. 1978 Jul 1;50(1):39-50. PubMed PMID: 28233.

16: Costall B, Naylor RJ, Owen RT. Gabaminergic and serotonergic modulation of the antidyskinetic effects of tiapride and oxiperomide in the model using 2-(N,N-dipropyl)animo-5,6-dihydroxytetralin. Eur J Pharmacol. 1978 Jun 15;49(4):407-13. PubMed PMID: 352713.

17: Bédard P, Parkes JD, Marsden CD. Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias. Br Med J. 1978 Apr 15;1(6118):954-6. PubMed PMID: 638546; PubMed Central PMCID: PMC1603806.

18: Costall B, Naylor RJ. Dissociation of stereotyped biting responses and oro-bucco-lingual dyskinesias. Eur J Pharmacol. 1976 Apr;36(2):423-9. PubMed PMID: 945168.

19: Costall B, Naylor RJ. Neuroleptic antagonism of dyskinetic phenomena. Eur J Pharmacol. 1975 Sep-Oct;33(2):301-12. PubMed PMID: 241654.